Alterity Therapeutics announced FDA agreement on a clear regulatory pathway for its drug ATH434 to treat Multiple System Atrophy (MSA), a rare neurodegenerative disease. The FDA confirmed that a single pivotal Phase 3 trial plus confirmatory evidence from Phase 2 data could support drug approval. Alterity plans to start the Phase 3 trial by the end of 2026, enrolling about 200 patients. The company also received a A$3.98 million R&D tax refund and holds A$37.3 million in cash, supporting ongoing development and strategic funding discussions to maximize shareholder value.
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Russian authorities have put Telegram founder Pavel Durov on an international wanted list, accusing him of facilitating terrorism. This move caused the GRAM token, linked to Telegram, to drop about 4% before partially recovering. The charges are broa...
Gold prices remain stable near critical support levels as the Bank of England kept interest rates unchanged at 3.75%, despite some members favoring a hike due to inflation driven by the global energy crisis. The central bank emphasized that monetary ...
In July 2026, Bitcoin spot ETFs attracted only $205 million in net inflows, the smallest monthly total on record, indicating weak institutional interest despite some daily inflows. This follows significant outflows in May and June. Ether ETFs perform...
